Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With TACE in Extrahepatic Cholangiocarcinoma
NCT05448183Phase 2Unknown
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in extrahepatic cholangiocarcinoma (eCCA). Status: unknown.
02
Drugs
toripalimab
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on NCT05448183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448183.